+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biosimilars of Factor X agonists Market by Product Type (Plasma-Derived Factor X, Recombinant Factor X), Indication (Acquired Hemorrhagic Conditions, Congenital Deficiency, Hemorrhagic Prophylaxis), Dosage Form, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Biosimilars of Factor X agonists Market by Product Type (Plasma-Derived Factor X, Recombinant Factor X), Indication (Acquired Hemorrhagic Conditions, Congenital Deficiency, Hemorrhagic Prophylaxis), Dosage Form, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Biosimilars of Factor X agonists Market by Product Type (Plasma-Derived Factor X, Recombinant Factor X), Indication (Acquired Hemorrhagic Conditions, Congenital Deficiency, Hemorrhagic Prophylaxis), Dosage Form, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6079267
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The biosimilars of Factor X agonists market is entering a stage of rapid innovation and expansion. There is growing momentum across product development, regulatory adaptation, and commercial alliances, setting the stage for transformative advances in hemostatic therapies nationwide.

Market Snapshot: Biosimilars of Factor X Agonists

The biosimilars revolution is driving significant shifts in the Factor X agonist landscape. Growing pricing pressures on biologics and increased demand for accessible, cost-effective treatments are fueling this market. Accelerated clinical development and the evolution of robust real-world evidence frameworks are attracting heightened interest from healthcare systems, addressing a broad range of congenital and acquired bleeding disorders. Industry consolidation, digital distribution models, and collaborative manufacturing efforts are further shaping the sector, enabling flexible, resilient supply networks and tailored market strategies.

Scope & Segmentation of the Factor X Biosimilars Market

  • Product Types: Includes plasma-derived Factor X and recombinant Factor X, each with distinct manufacturing and scalability considerations.
  • Indications: Encompasses acquired hemorrhagic conditions—such as those related to liver disease or induced by vitamin K antagonists—along with moderate and severe congenital deficiencies; also covers long-term hemorrhagic prophylaxis and perioperative use.
  • Dosage Forms: Covers both powder for injection and ready-to-use injectable formats, offering trade-offs between operational efficiency and preparation ease.
  • Distribution Channels: Spans hospital pharmacies (both inpatient and outpatient settings), online pharmacies using prescription and subscription models, and retail pharmacies including chain and independent operations.
  • End Users: Considers home healthcare (with nurse or self-administration), community and tertiary hospitals, specialty cardiology clinics, and dedicated hemophilia treatment centers.
  • Geographic Regions: Market coverage extends across the Americas, Europe, Middle East & Africa, and Asia-Pacific—including key markets such as the United States, Canada, major European economies, parts of the Middle East, Africa, China, India, and others.
  • Leading Players: Analysis focuses on companies including Sandoz International GmbH, Celltrion, Inc., Pfizer Inc., Samsung Bioepis Co., Ltd., Biocon Limited, Amgen Inc., Fresenius Kabi AG, Boehringer Ingelheim International GmbH, Viatris Inc., and Dr. Reddy’s Laboratories Limited.

Key Takeaways for Senior Decision-Makers

  • Rapid advancements in recombinant technology and strategic partnerships are enabling companies to diversify product portfolios and enhance patient access.
  • Shifting regulatory landscapes are creating opportunities for biosimilar developers to streamline clinical development and approval, leveraging harmonized guidelines and sophisticated analytical tools.
  • Payers increasingly require robust real-world evidence and pharmacovigilance data to support product interchangeability and long-term safety, influencing provider and patient adoption patterns.
  • Commercial alliances, such as co-development agreements and value-based contracting, are becoming pivotal in securing sustainable competitive advantage and reducing the total cost of care for healthcare systems.
  • Regional adaptations are essential, as local production incentives and regulatory flexibility vary considerably across markets, shaping both access and adoption.
  • Tariff policies—especially in the United States—affect global supply chains, pressuring manufacturers to reassess sourcing, pricing, and distribution strategies for uninterrupted patient access.

Tariff Impact: Navigating Supply and Cost Pressures

Recent U.S. tariff policies have disrupted global sourcing of raw materials and substrates, compelling manufacturers to diversify supplier networks and consider near-shoring. Increased duties have pushed up landed costs, amplified downstream pricing pressures, and prompted procurement innovation. In response, health systems are diversifying procurement channels while regional authorities encourage local production, striving for continuity in patient supply.

Methodology & Data Sources

This analysis is grounded in a dual methodology. Primary data was sourced through 50+ interviews with KOLs across clinical, regulatory, and payer groups. Secondary information included systematic reviews of scientific literature, regulatory filings, and company reports. Rigorous data validation and scenario modeling underpin the reliability of findings presented here.

Why This Report Matters

  • Facilitates informed market entry and expansion decisions by mapping high-impact segments, shifting regulations, and technology trends.
  • Enables strategic investment and partnership planning, drawing from granular regional insights and detailed competitor profiling.
  • Provides actionable recommendations for optimizing value-based contracting, supply chain resilience, and targeted commercial messaging.

Conclusion

The Factor X biosimilars landscape is reshaping hemostatic care through clinical, regulatory, and commercial innovation. Industry leaders positioned to adapt in this dynamic market will capture growth and elevate patient access to advanced therapies.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Regulatory breakthroughs in interchangeability designations for factor X agonist biosimilars driving market uptake
5.2. Clinical real-world evidence demonstrating efficacy and safety of factor X agonist biosimilars in diverse patient populations
5.3. Strategic collaborations between biopharma companies to enhance manufacturing scale of biosimilar factor X agonists
5.4. Patent litigation outcomes influencing market entry timelines for factor X agonist biosimilars globally
5.5. Cost-saving impact of factor X agonist biosimilars on healthcare budgets and payer reimbursement strategies
5.6. Supply chain optimization initiatives to ensure consistent availability of factor X agonist biosimilars
5.7. Rapid adoption patterns of factor X agonist biosimilars in emerging markets amid pricing pressures and access strategies
5.8. Digital health integration for monitoring patient response to factor X agonist biosimilars in clinical practice
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biosimilars of Factor X agonists Market, by Product Type
8.1. Introduction
8.2. Plasma-Derived Factor X
8.3. Recombinant Factor X
9. Biosimilars of Factor X agonists Market, by Indication
9.1. Introduction
9.2. Acquired Hemorrhagic Conditions
9.2.1. Liver Disease Related
9.2.2. Vitamin K Antagonist-Induced
9.3. Congenital Deficiency
9.3.1. Moderate Deficiency
9.3.2. Severe Deficiency
9.4. Hemorrhagic Prophylaxis
9.4.1. Long-Term Prophylaxis
9.4.2. Perioperative Prophylaxis
10. Biosimilars of Factor X agonists Market, by Dosage Form
10.1. Introduction
10.2. Powder For Injection
10.3. Ready-To-Use Injection
11. Biosimilars of Factor X agonists Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.2.1. Inpatient Pharmacy
11.2.2. Outpatient Pharmacy
11.3. Online Pharmacy
11.3.1. Prescription Service
11.3.2. Subscription Service
11.4. Retail Pharmacy
11.4.1. Chain Pharmacy
11.4.2. Independent Pharmacy
12. Biosimilars of Factor X agonists Market, by End User
12.1. Introduction
12.2. Home Healthcare
12.2.1. Nurse Administration
12.2.2. Self-Administration
12.3. Hospitals
12.3.1. Community Hospital
12.3.2. Tertiary Care Center
12.4. Specialty Clinics
12.4.1. Cardiology Clinic
12.4.2. Hemophilia Treatment Center
13. Americas Biosimilars of Factor X agonists Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Biosimilars of Factor X agonists Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Biosimilars of Factor X agonists Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Sandoz International GmbH
16.3.2. Celltrion, Inc.
16.3.3. Pfizer Inc.
16.3.4. Samsung Bioepis Co., Ltd.
16.3.5. Biocon Limited
16.3.6. Amgen Inc.
16.3.7. Fresenius Kabi AG
16.3.8. Boehringer Ingelheim International GmbH
16.3.9. Viatris Inc.
16.3.10. Dr. Reddy’s Laboratories Limited
17. Research AI18. Research Statistics19. Research Contacts20. Research Articles21. Appendix
List of Figures
FIGURE 1. BIOSIMILARS OF FACTOR X AGONISTS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BIOSIMILARS OF FACTOR X AGONISTS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BIOSIMILARS OF FACTOR X AGONISTS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. BIOSIMILARS OF FACTOR X AGONISTS MARKET: RESEARCHAI
FIGURE 26. BIOSIMILARS OF FACTOR X AGONISTS MARKET: RESEARCHSTATISTICS
FIGURE 27. BIOSIMILARS OF FACTOR X AGONISTS MARKET: RESEARCHCONTACTS
FIGURE 28. BIOSIMILARS OF FACTOR X AGONISTS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. BIOSIMILARS OF FACTOR X AGONISTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PLASMA-DERIVED FACTOR X, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PLASMA-DERIVED FACTOR X, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RECOMBINANT FACTOR X, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RECOMBINANT FACTOR X, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY LIVER DISEASE RELATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY LIVER DISEASE RELATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY VITAMIN K ANTAGONIST-INDUCED, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY VITAMIN K ANTAGONIST-INDUCED, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY MODERATE DEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY MODERATE DEFICIENCY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SEVERE DEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SEVERE DEFICIENCY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY LONG-TERM PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY LONG-TERM PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PERIOPERATIVE PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PERIOPERATIVE PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY POWDER FOR INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY POWDER FOR INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY READY-TO-USE INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY READY-TO-USE INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRESCRIPTION SERVICE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRESCRIPTION SERVICE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SUBSCRIPTION SERVICE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SUBSCRIPTION SERVICE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY NURSE ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY NURSE ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SELF-ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SELF-ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COMMUNITY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COMMUNITY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY TERTIARY CARE CENTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY TERTIARY CARE CENTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CARDIOLOGY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CARDIOLOGY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMOPHILIA TREATMENT CENTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMOPHILIA TREATMENT CENTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 159. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 160. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 161. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2024 (USD MILLION)
TABLE 164. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2025-2030 (USD MILLION)
TABLE 165. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 166. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 167. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 168. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 169. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 170. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 171. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 174. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 175. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 176. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 177. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 178. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 179. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 182. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 183. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 184. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 185. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 186. CANADA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 187. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 188. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 189. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 190. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 191. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2024 (USD MILLION)
TABLE 192. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2025-2030 (USD MILLION)
TABLE 193. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 194. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 195. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 196. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 197. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 198. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 199. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 202. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 203. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 204. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 205. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 206. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 207. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 210. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 211. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 212. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 213. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 214. MEXICO BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 238. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 239. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 240. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 241. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 242. BRAZIL BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MILLION)
TABLE 261. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 262. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 263. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 266. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 267. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 268. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 269. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 270. ARGENTINA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ACQUIRED HEMORRHAGIC CONDITIONS, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY CONGENITAL DEFICIENCY, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HEMORRHAGIC PROPHYLAXIS, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS OF FACTOR X AGONISTS MARKET SIZE, BY ONLINE PHARMACY, 2025-2030 (USD MI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Biosimilars of Factor X agonists market report include:
  • Sandoz International GmbH
  • Celltrion, Inc.
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Biocon Limited
  • Amgen Inc.
  • Fresenius Kabi AG
  • Boehringer Ingelheim International GmbH
  • Viatris Inc.
  • Dr. Reddy’s Laboratories Limited

Related Topics

Related Reports

Oral Biologics & Biosimilars Market Report 2025 - Product Image

Oral Biologics & Biosimilars Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market by Molecule Class (Anti Cd20, Anti Her2, Anti Vascular Endothelial Growth Factor), Indication (Inflammatory Bowel Disease, Neutropenia, Oncology), Dosage Form, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Biosimilar Monoclonal Antibodies Market by Molecule Class (Anti Cd20, Anti Her2, Anti Vascular Endothelial Growth Factor), Indication (Inflammatory Bowel Disease, Neutropenia, Oncology), Dosage Form, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Adalimumab Biosimilars Market by Indication, Distribution Channel, End User, Dosage Form, Route of Administration, Strength - Global Forecast 2025-2030 - Product Image

Adalimumab Biosimilars Market by Indication, Distribution Channel, End User, Dosage Form, Route of Administration, Strength - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA - Product Image

2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA

  • Report
  • 84 Pages
  • Global
From
Immunology Biosimilars Market (2024 Edition): Analysis By Indication (Arthritis, Irritable Bowel Disease, Other Indications), By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030) - Product Image

Immunology Biosimilars Market (2024 Edition): Analysis By Indication (Arthritis, Irritable Bowel Disease, Other Indications), By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)

  • Report
  • 202 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.